Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study

References

• Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of nonalcoholic fatty liver disease. Metabolism. 2016;65:1017–1025. doi:10.1016/j.metabol.2016.01.012
   PubMed Web of Science ®Google Scholar
• Liu JY, Ayada I, Zhang XF, et al. Estimating global prevalence of metabolic dysfunction associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20(3):e573-e582. doi: 10.1016/j.cgh.2021.02.030
   Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
   PubMed Web of Science ®Google Scholar
• Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109–1123. doi:10.1016/j.metabol.2016.05.003
   PubMed Web of Science ®Google Scholar
• Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32(1):22–29. doi:10.1055/s-0032-1306423
   Web of Science ®Google Scholar
• Yoneda M, Yamamoto T, Honda Y, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56(11):1022–1032. doi:10.1007/s00535-021-01828-6
   PubMed Web of Science ®Google Scholar
• Lin YS, Gong XR, Li X, et al. Distinct cause of death profiles of hospitalized non-alcoholic fatty liver disease: a 10 years’ cross-sectional multicenter study in China. Front Med. 2021;7:584396. doi:10.3389/fmed.2020.584396
   Web of Science ®Google Scholar
• Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc. 2010;85:349e56. doi:10.4065/mcp.2009.0365
   Web of Science ®Google Scholar
• Pastori D, Polimeni L, Baratta F, Pani A, Ben MD, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015;47:4–11. doi:10.1016/j.dld.2014.07.170
   Google Scholar
• Ahsan F, Oliveri F, Goud HK, et al. Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cureus. 2020;12(9):e10446. doi:10.7759/cureus.10446
   PubMed Web of Science ®Google Scholar
• Lee JI, Lee HW, Lee KS, Lee HS, Park JY. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study. Am J Gastroenterol. 2021;116(1):116–124. doi:10.14309/ajg.0000000000000845
   PubMed Web of Science ®Google Scholar
• Markova AA, Deterding K, Port K, et al. Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. Eur J Gastroenterol Hepatol. 2021;32(2):223–229. doi:10.1097/MEG.0000000000001719
   Web of Science ®Google Scholar
• Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 2017;71:17–32. doi:10.1016/j.metabol.2017.02.014
   PubMed Web of Science ®Google Scholar
• Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a non-invasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–854. doi:10.1002/hep.21496
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology. 2006;43:1317–1325. doi:10.1002/hep.21178
   PubMed Web of Science ®Google Scholar
• Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10. doi:10.7326/0003-4819-137-1-200207020-00006
   PubMed Web of Science ®Google Scholar
• Joint committee issued Chinese guideline for the management of dyslipidemia in adults. 2016 Chinese guideline for the management of dyslipidemia in adults. Chin J Cardiovasc Dis. 2016;44(10):833–853.
   Google Scholar
• Rzouq FS, Volk ML, Hatoum HH, Talluri SK, Mummadi RR, Sood GK. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci. 2010;340:89–93. doi:10.1097/MAJ.0b013e3181e15da8
   Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376(9756):1916–1922. doi:10.1016/S0140-6736(10)61272-X
   PubMed Web of Science ®Google Scholar
• Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of longterm multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomized ATTEMPT study. Arch Med Sci. 2011;7(5):796–805. doi:10.5114/aoms.2011.25554
   PubMed Web of Science ®Google Scholar
• Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. 2013;168:3846–3852. doi:10.1016/j.ijcard.2013.06.024
   PubMed Web of Science ®Google Scholar
• Hyogo H, Ikegami T, Tokushige K, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res. 2011;41(11):1057–1065. doi:10.1111/j.1872-034X.2011.00849.x
   PubMed Web of Science ®Google Scholar
• Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015;21(25):7860–7868. doi:10.3748/wjg.v21.i25.7860
   PubMed Web of Science ®Google Scholar
• Arguello G, Balboa E, Arrese M. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta. 2015;1852(9):1765–1778. doi:10.1016/j.bbadis.2015.05.015
   PubMed Web of Science ®Google Scholar
• Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726–735. doi:10.1053/j.gastro.2013.11.049
   PubMed Web of Science ®Google Scholar
• Islam MM, Poly TN, Walther BA, Yang HC, Jack L. Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies. Cancers. 2020;12(3):671. doi:10.3390/cancers12030671
   Web of Science ®Google Scholar
• Shiri-Sverdlov R, Wouters K, van Gorp PJ, et al. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. J Hepatol. 2006;44:732–741. doi:10.1016/j.jhep.2005.10.033
   PubMed Web of Science ®Google Scholar
• Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23:1464–1467. doi:10.1002/hep.510230624
   PubMed Web of Science ®Google Scholar
• Fernandez-Miranda C, Perez-Carreras M, Colina F, López-Alonso G, Vargas C, Solís-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40:200–205. doi:10.1016/j.dld.2007.10.002
   PubMedGoogle Scholar
• Goyal O, Nohria S, Goyal P, et al. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020;10(1):21117. doi:10.1038/s41598-020-78342-x
   Web of Science ®Google Scholar
• Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292(5519):1160–1164. doi:10.1126/science.1059344
   PubMed Web of Science ®Google Scholar
• Prieur X, Coste H, Rodriguez JC. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-alpha and contains a novel farnesoid X-activated receptor response element. J Biol Chem. 2003;278(28):25468–25480. doi:10.1074/jbc.M301302200
   PubMed Web of Science ®Google Scholar
• Vu-Dac N, Gervois P, Jakel H, et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem. 2003;278(20):17982–17985. doi:10.1074/jbc.M212191200
   Web of Science ®Google Scholar
• Jani RH, Kansagra K, Jain MR, et al. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013;33:809–816. doi:10.1007/s40261-013-0128-3
   PubMed Web of Science ®Google Scholar
• Wong ND, Chuang J, Wong K, et al. Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009–2010). Am J Cardiol. 2013;112:373–379. doi:10.1016/j.amjcard.2013.03.041
   PubMed Web of Science ®Google Scholar
• Toth PP, Zarotsky V, Sullivan JM, Laitinen D. Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis. Cardiovasc Diabetol. 2009;8:26. doi:10.1186/1475-2840-8-26
   Web of Science ®Google Scholar
• Khoo S, Wong VW, Goh GB, et al. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2020;35(2):320–325. doi:10.1111/jgh.14794
   Web of Science ®Google Scholar